Oxygen Of The Saccharide Radical Bonded Directly To A Polycyclo Ring System Of Three Or More Carbocyclic Rings Patents (Class 514/33)
-
PHARMACEUTICAL COMPOSITION AND METHOD FOR REGENERATING MYOFIBERS IN THE TREATMENT OF MUSCLE INJURIES
Publication number: 20090028959Abstract: A pharmaceutical composition and method for regenerating cardiomyocytes in treating or repairing heart muscle damages or injuries caused by an ischemic disease. The pharmaceutical composition contains an active ingredient compound with a backbone structure of Formula (I). The active ingredient compound is capable of (a) increasing viability of myogenic precursor cells to enable said precursor cells to survive through an absolute ischemic period; (b) reconstituting a damaged blood supply network in said heart region where said injured muscle is located; and (c) enhancing cardiomyogenic differentiation efficiency of said precursor cells down cardiac linage, said steps being performed simultaneously or in any particular order.Type: ApplicationFiled: October 27, 2006Publication date: January 29, 2009Inventors: Ming Li, Lei Cheng, Wei Liu Hong -
Publication number: 20090005302Abstract: Anthracyclin-treated turn or cells are particularly effective in eliciting an anti-cancer immune response, where the rDNA-damaging agents, such as etoposide and mitomycin C do not induce immunogenic cell death. Anthracyclins induce the rapid, pre-apoptotic translocation of calreticulin (CRT) to the cell surface. Blockade or knock down of CRT suppressed the phagocytosis of anthracyclin-treated tumor cells by dendritic cells and abolished their immunogenicity in mammals, such as mice. The anthracyclin-induced CRT translocation was mimicked by inhibition of the protein phosphatase1/GADD34 complex. Administration of recombinant CRT or inhibitors of protein phosphatase1/GADD34 restored the immunogenicity of cell death elicited by etoposide and mitomycin C, and enhanced their antitumor effects in vivo. These data identify CRT as a key feature determining anti-cancer immune responses and delineate a possible strategy for immunogenic chemotherapy.Type: ApplicationFiled: July 7, 2007Publication date: January 1, 2009Inventor: Michel Sarkis OBEID
-
Publication number: 20080279933Abstract: This invention is a novel pharmaceutical composition comprising flurbiprofen or a pharmaceutically acceptable salt thereof in combination with an ?-2 adrenergic receptor agonist or a gamma-aminobutiric acid receptor agonist with anti-inflammatory, analgesic and myorelaxant activity.Type: ApplicationFiled: May 8, 2008Publication date: November 13, 2008Applicant: Sanovel Ilac Sanayi Ve Ticaret A.S.Inventors: Umit Cifter, Ali Turkyilmaz, Hasan Ali Turp
-
Publication number: 20080274121Abstract: We disclose a method of inhibiting angiogenesis in a mammal by administering by a subcutaneous or intraperitoneal route to a tissue in the mammal where angiogenesis is occurring a composition comprising mithramycin and a pharmaceutically-acceptable carrier. We have found a subcutaneous or intraperitoneal dose from about 10 ?g mithramycin per kg body weight per day to about 500 ?g mithramycin per kg body weight per day can be effective for inhibition of angiogenesis.Type: ApplicationFiled: April 30, 2008Publication date: November 6, 2008Inventors: James C. Yao, Keping Xie
-
Patent number: 7435756Abstract: The present invention relates to application of compounds of formula (1) (Gibberellins) and their derivatives for the preparation of a pharmaceutical composition or medicaments for the treatment of diabetes, its complications and associated conditions, including obesity, micro and macro vascular diseases, nephropathy, neuropathy, eye diseases, diabetic ulcerations and the like.Type: GrantFiled: February 12, 2004Date of Patent: October 14, 2008Assignee: Australian Biomedical Company Pty, Ltd.Inventors: Peter James Jenkins, Minnie Wu, David Shine Wu
-
Publication number: 20080206169Abstract: Personal care composition comprising at least one skin care active selected from the group consisting of acetyl glutamic acid, acetyl glutamine, acetyl methionine, acetyl tributyl citrate, acetyl triethyl citrate, acetyl tyrosine, adipic acid, alanine, arginine, arginine glutamate, benzophenone-3, camphor, gluconolactone, glucose, glycine, histidine hydrochloride, hydroxyproline, maltitol, phenylalanine, succinic acid, buffered lactic acid, tris(tetramethylhydroxypiperidinol) citrate, a boswellic acid compound, and salts, isomers, derivatives, and mixtures of any of the foregoing; and a dermatologically acceptable carrier.Type: ApplicationFiled: November 15, 2007Publication date: August 28, 2008Inventors: Cheri Lynn Millikin, Donald Lynn Bissett
-
Publication number: 20080194499Abstract: The present invention relates to a novel pharmaceutical composition for serotonin reuptake inhibition, wherein the composition comprises pentacyclic terpenoid glycosides, preferably asiaticoside and madecassoside optionally along with excipients. Also the present invention relates to a process of preparation of novel pharmaceutical composition for serotonin reuptake inhibition, wherein the process comprising steps of: (a) obtaining extract from the plant Centella asiatica; (b) treating the extract with the solvents to remove fatty substances, chlorophyll and other colorants; (c) purifying the extract through HPLC to obtain the eluted solvent; and (d) concentrating the eluted solvent to arrive at the composition. The invention also relates to the use of a composition comprising pentacyclic terpenoid glycosides, preferably asiaticoside and madecassoside optionally along with excipients to manufacture a medicament for serotonin reuptake inhibition in a subject in need thereof.Type: ApplicationFiled: February 12, 2008Publication date: August 14, 2008Applicant: INDUS BIOTECH PRIVATE LIMITEDInventors: Sunil Bhaskaran, Mohan Vishwaraman
-
Publication number: 20080171787Abstract: Colchicine neoglycosides, method for their synthesis and methods for their use are disclosed. The invention provides analogs of colchicine glycosylated to include a sugar moiety on a colchicine scaffold that is generally unglycosylated in nature. The colchicine neoglycosides disclosed herein are shown to have cytotoxic effects equivalent to at least the known cytotoxins paclitaxel and doxorubicin. Further, the neoglycosides disclosed according to the invention have physiologic effects not previously recognized in the alkaloid family that includes colchicine but recognized in other cytotoxic drug families such as the taxanes which act by stabilizing tubulin formation.Type: ApplicationFiled: October 8, 2007Publication date: July 17, 2008Applicant: Wisconsin Alumni Research FoundationInventors: Jon S. Thorson, Ahmed Aqeel
-
Patent number: 7387790Abstract: Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.Type: GrantFiled: June 14, 2002Date of Patent: June 17, 2008Assignee: Cornerstone PharmaceuticalsInventors: Robert Shorr, Robert Rodriguez
-
Publication number: 20080124303Abstract: A novel method of treating and preventing viral diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of viral infections and the diseases associated with such viral infections. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made compositions comprising a substance exhibiting Tubercin and/or SSM activity or a functional derivative thereof.Type: ApplicationFiled: July 12, 2007Publication date: May 29, 2008Inventor: Colm King
-
Publication number: 20080119420Abstract: Two hitherto unreported novel triterpene saponins were isolated in substantially pure form from the root of Ilex pubescens. The chemical structures and some properties of the triterpene saponin fraction have been elucidated to possess anti-inflammatory and analgesic activity. These two novel triterpene saponins and the triterpene saponin fraction may be used as pharmaceutical compositions in humans and mammals in need of such treatment.Type: ApplicationFiled: November 17, 2006Publication date: May 22, 2008Inventors: Liang LIU, Jing Rong Wang, Hua Zhou, Zhi Hong Jiang
-
Patent number: 7371889Abstract: The invention relates to new chemical compounds that inhibit the various enzymes in the arachidonic acid pathway implicated in inflammatory disease conditions.Type: GrantFiled: March 11, 2007Date of Patent: May 13, 2008Assignee: Sami Labs LimitedInventors: Muhammed Majeed, Kalyanam Nagebhuananam, Rajendran Ramanujam, Subbalakshmi Prakash
-
Patent number: 7323452Abstract: A method for accelerating the process of removing ethanol from the blood through the use of certain additives that accelerate the metabolic oxidation of ethanol, and others which in addition act as catalysts or “pseudo” enzymes for the oxidation. These additives include multivalent transition metal ions, as well as complexes thereof, and NAD+ which enhance the oxidation reaction. The method described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.Type: GrantFiled: December 20, 2004Date of Patent: January 29, 2008Assignee: Wardan, L.L.C.Inventors: Ward B. Bowen, Jr., Daniel S. Daniel
-
Patent number: 7288534Abstract: Cytotoxic tumor therapy in a patient is enhanced by co-administration of sphingomyelin. The invention most likely enhances a tumor cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. A method of treating rheumatoid arthritis also is provided.Type: GrantFiled: February 14, 2003Date of Patent: October 30, 2007Assignee: Center for Molecular Medicine and ImmunologyInventors: David Modrak, David M. Goldenberg
-
Publication number: 20070249543Abstract: A phyto-pharmacological substance, namely a saponin, precursor or derivative, with emulsifying/detergent/surfactant/fat dissolving properties administered into the systemic circulation of a subject via a variety of routes of administration including the topical-dermatological such as a skin patch, the oral-digestive in association with solubility or permeability or stability enhancers, alone or in synergitic combination, the topical-mucous membrane administration such as the sublingual route, the intravenous, subcutaneous, rectal, intramuscular, intradermal, inhalatory in form of inhaled microcrystals, the intrarterial, the saponin substance reaching and dissolving with its emulsifying properties the cholesterol aggregates and in general the lipidic core within the atherosclerotic plaque.Type: ApplicationFiled: October 4, 2006Publication date: October 25, 2007Inventors: Filiberto Zadini, Giorgio Zadini
-
Publication number: 20070243238Abstract: A method for treating a mouth sore opposite a tooth by adhering an oral patch on the tooth to speed healing and relieve pain. The oral patch is placed either directly on the portion of the tooth that comes into contact with the sore or is first place onto the sore and then adhered to the tooth. The patch may be a blob of hydrophilic gums. If certain medications are applied to a mouth sore using an oral patch that delivers the medication for at least 30 minutes and the patches are used for at least two or more hours per day, the method reduces the healing time for mouth sores from typical 10-14 days to 1-5 days. The method can be used with various antimicrobials, glucocorticoids or anthihistamines incorporated into the patch that reduce inflammation or speed the healing of mouth sores.Type: ApplicationFiled: December 15, 2006Publication date: October 18, 2007Inventor: Jeffrey T. Haley
-
Patent number: 7262285Abstract: Novel compounds such as compounds designated herein as Xanifolia-Y or -Y3, -Y1, -Y2, -Y8, -Y9 and -Y10 are disclosed. These compounds have anticancer activity. The compounds of the present invention are obtainable from plants in the sapindaceae family, such as Xanthoceras sorbifolia, or other natural sources or products.Type: GrantFiled: May 17, 2005Date of Patent: August 28, 2007Assignee: Pacific Arrow LimitedInventors: Pui-Kwong Chan, May Sung Mak, Yun Wang
-
Patent number: 7232805Abstract: The present invention provides a cobalamin-drug conjugate suitable for the treatment of tumor related diseases. Cobalamin is indirectly covalently bound to an anti-tumor drug via a cleavable linker and one or more optional spacers. Cobalamin is covalently bound to a first spacer or the cleavable linker via the 5?-OH of the cobalamin ribose ring. The drug is bound to a second spacer of the cleavable linker via an existing or added functional group on the drug. After administration, the conjugate forms a complex with transcobalamin (any of its isoforms). The complex then binds to a receptor on a cell membrane and is taken up into the cell. Once in the cell, an intracellular enzyme cleaves the conjugate thereby releasing the drug. Depending upon the structure of the conjugate, a particular class or type of intracellular enzyme affects the cleavage. Due to the high demand for cobalamin in growing cells, tumor cells typically take up a higher percentage of the conjugate than do normal non-growing cells.Type: GrantFiled: September 10, 2003Date of Patent: June 19, 2007Assignee: Inflabloc Pharmaceuticals, Inc.Inventors: Ned M. Weinshenker, Frederick G. West, Barbara A. Araneo, Weiping Li
-
Patent number: 7220428Abstract: Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.Type: GrantFiled: October 27, 2004Date of Patent: May 22, 2007Assignee: Cornerstone PharmaceuticalsInventors: Robert Shorr, Robert Rodriguez
-
Patent number: 7204996Abstract: This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of (a) evaluating the subject to determine if the subject has relapsed or refractory cancer; (b) administering a high-dose amount of liposomal-annamycin for at least 3 days in a 7 day period. First line cancer therapy with particular reference to leukemia is both contemplated and useful.Type: GrantFiled: June 10, 2005Date of Patent: April 17, 2007Assignee: Board of Regents, The University of Texas SystemInventors: Michael Andreeff, Elihu H Estey
-
Patent number: 7202222Abstract: Methods for treating obesity, reducing total weight and reducing body fat mass by administering a composition comprising dihydroquercetins and root-derived aralosides A, B, C and D is disclosed.Type: GrantFiled: September 11, 2003Date of Patent: April 10, 2007Assignee: National Bioscience CorporationInventors: Arthur Ramazanov, Zakir Ramazanov
-
Patent number: 7163702Abstract: This present invention discloses use of a chloroform/solvent mixture extraction at different solvent-to-feed ratios, followed by evaporation and extraction with ethyl acetate/water; followed by chromatography of the water phase in Teflon or other non-polar resin and Silica gel column chromatography for recovering of individual triterpene glycosides (saponins) of high purity from the freeze dried or spray dried cooking water or dried powderized tissues of the industrial processed sea cucumber Cucumaria frondosa. A resulting glycoside Frondoside A stimulates lysosomal activity of peritoneal macrophages, phagocytosis and oxidative burst in the macrophages at concentrations significantly less than for acute toxicity, hemolysis and sea urchin embryo toxicity.Type: GrantFiled: June 6, 2005Date of Patent: January 16, 2007Inventors: Sergey Anatolievuch Avilov, Vladimir Ivanovich Kalinin, Alexandra Sergeevna Silchenko, Dmitry Lvovich Aminin, Irina Grigorevna Agafonova, Valentin Aronovich Stonik, Peter D. Collin, Carl Woodward
-
Patent number: 7157078Abstract: This invention relates to devices, kits, and methods for eliminating termite colonies. The kits, devices, and methods employ a termiticidal bait matrix containing a) a termiticide selected such that the termiticide causes death to about 50 to about 100% of termites within about 24 to about 84 days after the termites begin to ingest the termiticide or the bait matrix comprising the termiticide, b) a cellulose containing material, and c) water. The termiticidal bait matrix can be used in a bait station installed in the ground. The kits are suitable to be used by consumers in their homes.Type: GrantFiled: February 2, 2004Date of Patent: January 2, 2007Assignee: The University of Florida Research Foundation, Inc.Inventors: Philip Frederick Brode, III, Garry Steven Garren, Leo Timothy Laughlin, Randall Stryker Matthews, Dale Edwin Barker, Daniel James Kinne, Gary Eugene McKibben, Christopher Miles Miller, Timothy Robert Probst
-
Patent number: 7153877Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.Type: GrantFiled: December 9, 2004Date of Patent: December 26, 2006Assignee: Interhealth Nutraceuticals IncorporatedInventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
-
Patent number: 7144867Abstract: The present invention relates to new classes of anti-cancer compounds. In particular, the present invention provides glycoside compounds as anti-cancer agent, alone, or in combination with other anti-cancer agents or therapies.Type: GrantFiled: January 27, 2005Date of Patent: December 5, 2006Assignees: Northwestern University, Coastside Bio ResourcesInventors: Thomas E. Adrian, Peter D. Collin
-
Patent number: 7132403Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.Type: GrantFiled: January 20, 2004Date of Patent: November 7, 2006Assignees: Board of Trustees of Michigan State University, Regents of the University of CaliforniaInventors: Robert H. Cichewicz, Muraleedharan G. Nair, James H. McKerrow
-
Patent number: 7119110Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.Type: GrantFiled: October 4, 2002Date of Patent: October 10, 2006Assignee: Interhealth Nutraceuticals IncorporatedInventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
-
Patent number: 7105492Abstract: Camptothecin derivatives of camptothecin of formula (I) exhibit antitumor activity and show a good therapeutic index and are used in the treatment of tumors, viral infections and antiplasmodium falciparum.Type: GrantFiled: March 17, 2003Date of Patent: September 12, 2006Assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Istituo Nazionale Per Lo Studio E La Cura Dei TumoriInventors: Sabrina Dallavalle, Sergio Penco, Claudio Pisano, Franco Zunino
-
Patent number: 7094431Abstract: This invention pertains to therapeutic antibacterial/antifungal-wound healing compositions comprising a therapeutically effective amount of antibacterial agents and/or antifungal agents and/or wound healing composition alone. In one embodiment, the wound healing composition comprises (a) zinc oxide; (b) calcium channel blocker, and (c) fat-soluble vitamins admixed with antibacterial and antifungal agents. The therapeutic antibacterial/antifungal-wound healing compositions may be utilized in a wide variety of pharmaceutical products and administered orally or topically.Type: GrantFiled: September 30, 2003Date of Patent: August 22, 2006Inventor: Mickey L. Peshoff
-
Patent number: 7091189Abstract: By using a combination of amrubicin or a pharmaceutically acceptable salt thereof with another medicament for treating lung cancer (irinotecan, vinorelbine, gemcitabine, etc.), it is intended to provide medicaments for treating lung cancer having an improved antitumor therapeutic effect on lung cancer and reduced side effects. Lung cancer can be effectively treated using these medicaments.Type: GrantFiled: March 17, 2003Date of Patent: August 15, 2006Inventors: Toshihiro Noguchi, Akemi Baba
-
Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases
Patent number: 7071233Abstract: An improved medical treatment and medicine is provided to quickly and safely resolve HIV and other microbial infections. The inexpensive medicine can be self administered and maintained for the prescribed time. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent and a nutrient. In the preferred form, the medicine comprises: Echinacea and Commiphora myrrha phytochemicals, benzalkonium chloride, a sterile water solution, and folic acid.Type: GrantFiled: February 26, 2002Date of Patent: July 4, 2006Inventor: Meryl Squires -
Patent number: 7060686Abstract: Methods for treating, preventing, or inhibiting diseases and disorders associated with inflammation, cell-proliferation, and pain comprising the administration of a compound having the structural formula wherein R1 is a hydrogen, alkyl, aryl, hydroxyalkyl, cycloalkyl, cycloalkenyl, carboxylic acid, alkylamino or amide group having from 2 to 20 carbon atoms, R2, R3, and R4 are each independently hydrogen or an acyl residue having from 1 to 6 carbon atoms, R5 is hydrogen, CH3, or CH2OH, and R6 is an organo group such as a hydrocarbon having from 1 to 10 carbon atoms are disclosed. Other seco-pseudopterosins and compounds related to pseudopterosins are disclosed.Type: GrantFiled: August 2, 2004Date of Patent: June 13, 2006Assignees: The Regents of the University of California, Florida Atlantic University Board of TrusteesInventors: Robert S. Jacobs, Russell G. Kerr
-
Patent number: 7049301Abstract: This invention relates to quercetin derivative, its preparation, and a pharmaceutical combination, as well as their medical uses for the prevention or treatment of diseases related to 5HT1A receptor or neuron cell damages, including Alzeheimer's disease, drug or alcohol dependence, sleep disorders or panic state; and for delaying senility, improving learning and memory, preventing and treatment of neuron cell damages caused by various kinds of cerebral damages.Type: GrantFiled: September 26, 2003Date of Patent: May 23, 2006Assignee: Academy of Military Medical Sciences Institute of Pharmacology and ToxicologyInventors: Yimin Zhao, Ming Yang, Yunfeng Li, Xinhui Luan, Zhipu Luo
-
Patent number: 7008648Abstract: A method of suppressing or curbing appetite and treating or preventing obesity comprising administering to a human or other mammal in need of such treatment an effective amount of plant material derived or derivable from plants of the genera Stapelia and Orbea.Type: GrantFiled: November 4, 2002Date of Patent: March 7, 2006Assignee: Novartis Nutrition AGInventors: David Gregory Corley, James Miller
-
Patent number: 7008929Abstract: The present invention relates to the use of a sapogenin, chosen from diosgenin and hecogenin, and/or of a plant extract containing at least one of these sapogenins. A preferred use is the treatment of oligoseborrheic dry skin. Another preferred use is the treatment of dry scalp. Compositions containing these sapogenins are also described.Type: GrantFiled: March 24, 2003Date of Patent: March 7, 2006Assignee: L'OrealInventors: Gilles Rubinstenn, Bruno Buan
-
Patent number: 6946490Abstract: An improved medical treatment and medicine is provided to quickly and safely resolve herpes and other microbial infections. The inexpensive user-friendly medicine can be applied and maintained on the infected region until the physical symptoms of the disease disappears and the patient is comfortable and has a normal appearance. The attractive medicine comprises an antimicrobial concentrate comprising microbe inhibitors, phytochemicals or isolates. Desirably, the effective medicine comprises a surfactant and an aqueous carrier or solvent. In the preferred form, the medicine comprises Echinacea phytochemicals and benzalkonium chloride in a sterile water solution.Type: GrantFiled: March 7, 2002Date of Patent: September 20, 2005Inventor: Meryl Squires
-
Patent number: 6929802Abstract: This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of (a) evaluating the subject to determine if the subject has relapsed or refractory cancer; (b) administering a high-dose amount of liposomal-annamycin for at least 3 days in a 7 day period. First line cancer therapy with particular reference to leukemia is both contemplated and useful.Type: GrantFiled: April 18, 2003Date of Patent: August 16, 2005Assignee: Board of Regents, The University of Texas SystemInventors: Michael Andreeff, Elihu H. Estey
-
Patent number: 6903076Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.Type: GrantFiled: November 26, 2003Date of Patent: June 7, 2005Assignees: Board of Trustees of Michigan State University, The Regents of the University of CaliforniaInventors: Robert H. Cichewicz, Muraleedharan G. Nair, James H. McKerrow
-
Patent number: 6900239Abstract: A method for enhancing the efficacy of chemotherapy in the treatment of cancer in animals, particularly humans, is provided wherein isocoumarin derivatives that exhibit unique chemopotentiation properties are employed in a combination treatment with chemotherapy.Type: GrantFiled: February 23, 2002Date of Patent: May 31, 2005Assignee: ILWZ ILEX Products, Inc.Inventors: Naoki Agata, Surender Kharbanda
-
Patent number: 6894030Abstract: The synergistic combination of a loop diuretic and a cardiac glycoside is useful in the treatment of DNA viral infections.Type: GrantFiled: December 13, 2000Date of Patent: May 17, 2005Assignee: Henderson Morley Research and Development LimitedInventor: Christopher Edward Hartley
-
Patent number: 6875746Abstract: Anthraquinones are described which have anticancer or antitumor activity and which are useful for inhibiting cancer cells and cells comprising tumors in vitro or in vivo. Preferably, the anthraquinones have the chemical formula: wherein R1 is selected from the group consisting of hydrogen, alkyl, and substituted alkyl; R2 is a group containing 1-12 carbons selected from the group consisting of alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate and combinations thereof; and R3 is a group containing 1 to 12 carbons selected from the group consisting of methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, and combinations thereof.Type: GrantFiled: January 31, 2003Date of Patent: April 5, 2005Assignee: Board of Trustees of Michigan State UniversityInventors: Muraleedharan G. Nair, Robert H. Cichewicz, Navindra P. Seeram, Yanjun Zhang
-
Patent number: 6875745Abstract: We have discovered that the administration of a G1 and/or S phase drug such as ?-lapachone in combination with a G2/M drug such as a taxane derivative such as paclitaxel resulted in a greater than additive (i.e., synergistic) reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed. The present invention relates to a method for treating a mammalian tumor using combinations such as a taxane derivative, preferably paclitaxel, and a ?-lapachone, or a derivative or analog thereof.Type: GrantFiled: October 9, 2003Date of Patent: April 5, 2005Assignee: Dana Farber Cancer Institute, Inc.Inventors: Arthur B. Pardee, Chiang J. Li, Youzhi Li
-
Patent number: 6872709Abstract: The present invention provides a therapeutic agent and therapeutic method for treatment of mastitis in livestock comprising glycyrrhizin and pharmaceutically acceptable salts thereof as effective ingredients.Type: GrantFiled: July 28, 2003Date of Patent: March 29, 2005Assignee: Kyoritsu Seiyaku CorporationInventors: Katsuo Kumagai, Kenzo Kai, Ken-ichi Komine
-
Patent number: 6852694Abstract: The present invention is directed to stabilized insulin composition comprising a mixture of insulin species such as insulin and an insulin analog. As disclosed herein, insulin compositions comprising a mixture of insulin and insulin analog species form heterodimeric complexes having a greater stability than the homodimeric complexes formed in compositions comprising single insulin species. Consequently, the present invention provides methods for stabilizing insulin molecules, methods for identifying stable heterodimeric insulin complexes and stabilized insulin compositions.Type: GrantFiled: February 21, 2002Date of Patent: February 8, 2005Assignee: Medtronic MiniMed, Inc.Inventors: William Peter Van Antwerp, Poonam S. Gulati
-
Patent number: 6838443Abstract: Anthraquinones are described which are antihelminthic and in particular, are useful in compositions for inhibiting Schistosoma sp. in vitro or in vivo. The preferred anthraquinones have the formula: wherein R1, R2, R3, and R4 are each hydrogen, hydroxy, halogen, alkyl, substituted alkyl, alkene, substituted alkene, alkyne, aryl, substituted aryl, cyclic, substituted cyclic, acid group, carbohydrate, or combination thereof, R is a group containing 1 to 12 carbons such as methyl, alkyl, substituted alkyl, aldehyde, hydroxy, hydroxymethyl, acid group, carbohydrate, or combination thereof, and the halogen is I, F, Br, or Cl.Type: GrantFiled: November 26, 2003Date of Patent: January 4, 2005Assignees: Board of Trustees of Michigan State University, The Regents of the University of California, The United States of America as represented by the Department of Veterans AffairsInventors: Robert H. Cichewicz, Muraleedharan G. Nair, James H. McKerrow
-
Patent number: 6833443Abstract: This invention relates to new Gymnemic acid derivatives, their preparation, pharmaceutical composition or extract which contains them, and their medical use, especially the use in the prevention or treatment of the diseases associated with hyperglycemia, hyperlipidemia and platelets aggregation.Type: GrantFiled: January 15, 2002Date of Patent: December 21, 2004Assignee: Guilin Jiqi Pharmaceutical Co., Ltd.Inventors: Wencai Ye, Yue Dai, Xiaodong Cong, Xingxiang Zhu, Shouxun Zhao
-
Patent number: 6833362Abstract: A composition for accelerating the disposal of ethanol from bodily fluid. Certain additives can accelerate the metabolic oxidation of ethanol, and others in addition act as catalysts or “pseudo” enzymes for the oxidation. Additives include the oxidant Nicotinamide Adenine Dinucleotide and a variety of other additives such as transition metal ions and complexes thereof which favor the oxidation reaction. The compositions described can act as a sobriety inducer and/or as an effective palliative for the unpleasant effects of overuse of ethanol.Type: GrantFiled: June 7, 2001Date of Patent: December 21, 2004Inventors: Ward Beryl Bowen, Jr., Daniel Salman Daniel
-
Publication number: 20040247700Abstract: Compositions comprising an effective amount of a curcuminoid species and an effective amount of a diterpene lactone species, a triterpene species or derivatives thereof that have a synergistic effect on specific inhibition of inducible COX-2 activity and have minimal effect on COX-1 activity are disclosed. Methods of using the compositions for providing synergistic anti-inflammatory effects are also disclosed.Type: ApplicationFiled: July 1, 2004Publication date: December 9, 2004Inventors: John G. Babish, Terrence Howell, Linda Pacioretty
-
Publication number: 20040247703Abstract: Disclosed is a composition for inhibiting glutamate-mediated neurotoxicity comprising 20(S)-ginsenoside Rg3, 20(S)-ginsenoside Rh2 or the mixture of 20(S)-ginsenoside Rg3 and 20(S)-ginsenoside Rh2. The composition of the present invention has an excellent neurotoxicity inhibition effect or nerve cell protection effect. Accordingly, it can be effectively used for treating nervous diseases including cerebral trauma, cerebral apoplexy, cerebral hemorrhage; epilepsy occurred by excessive activation of glutamate receptors; or Huntington's disease.Type: ApplicationFiled: October 27, 2003Publication date: December 9, 2004Inventors: Hyewhon Rhim, Sunoh Kim
-
Publication number: 20040241173Abstract: A fullerene-antibiotic conjugate including at least one antibiotic molecule per fullerene moiety. The fullerene may comprise C60 and the antibiotic may comprise vancomycin or may be selected from the group consisting of penicillins, cephalosporins, quinolones, fluoroquinolones, macrolides, lincosamines, carbepenems, conobactams, aminoglycosides, glycopeptides, tetracyclines, sulfonamides, rifampin, oxazolidonones, and streptogramins. The conjugate preferably includes at least two and more preferably at least three antibiotic molecules per C60 center. A method for making a fullerene(C60)-antibiotic conjugate, comprises: synthesizing a linker precursor (I); reacting the linker precursor (I) with C60 via a Bingel-reaction, to produce a fullerene-linker conjugate (II); hydrolyzing the fullerene-linker conjugate (II), resulting in a desired derivative of C60 (III); and reacting the derivative (III) with a desired antibiotic to produce a fullerene-antibiotic conjugate (IV).Type: ApplicationFiled: February 11, 2004Publication date: December 2, 2004Applicant: William Marsh Rice UniversityInventors: Lon J. Wilson, Andrey L. Mirakyan, Matthew P. Cubbage